BioAmber Company Profile (NYSE:BIOA)

About BioAmber (NYSE:BIOA)

BioAmber logoBioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Industry, Sector and Symbol:
  • Sector: Basic Materials
  • Industry: Specialty Chemicals
  • Sub-Industry: N/A
  • Symbol: NYSE:BIOA
  • CUSIP: N/A
  • Web:
  • Market Cap: $27.06 million
  • Outstanding Shares: 37,102,000
Average Prices:
  • 50 Day Moving Avg: $0.65
  • 200 Day Moving Avg: $1.96
  • 52 Week Range: $0.32 - $6.50
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $10.54 million
  • Price / Sales: 1.83
  • Book Value: $1.86 per share
  • Price / Book: 0.28
  • EBIDTA: ($24,980,000.00)
  • Net Margins: -221.82%
  • Return on Equity: -56.55%
  • Return on Assets: -21.56%
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 1.50%
  • Quick Ratio: 1.03%
  • Average Volume: 1.09 million shs.
  • Beta: 2.7

Frequently Asked Questions for BioAmber (NYSE:BIOA)

What is BioAmber's stock symbol?

BioAmber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."

How were BioAmber's earnings last quarter?

BioAmber Inc. (NYSE:BIOA) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.03. The firm earned $4.12 million during the quarter, compared to analyst estimates of $4.09 million. BioAmber had a negative net margin of 221.82% and a negative return on equity of 56.55%. View BioAmber's Earnings History.

When will BioAmber make its next earnings announcement?

BioAmber is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for BioAmber.

Where is BioAmber's stock going? Where will BioAmber's stock price be in 2017?

1 brokerages have issued 12 month price targets for BioAmber's stock. Their forecasts range from $3.00 to $3.00. On average, they expect BioAmber's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for BioAmber.

Who are some of BioAmber's key competitors?

Who are BioAmber's key executives?

BioAmber's management team includes the folowing people:

  • Raymond J. Land, Chairman of the Board
  • Fabrice Orecchioni, President, Chief Operating Officer
  • Mario Settino, Chief Financial Officer
  • Michael A. Hartmann, Executive Vice President
  • James Millis, Chief Technology Officer
  • Robert Frost, Director
  • Kurt W. Briner, Independent Director
  • Heinz Haller, Independent Director
  • Ellen B. Richstone, Independent Director
  • Kenneth W Wall, Independent Director

Who owns BioAmber stock?

BioAmber's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include NN Investment Partners Holdings N.V. (7.73%), FMR LLC (3.67%), Robecosam AG (2.18%), Royce & Associates LP (2.09%), Baillie Gifford & Co. (1.56%) and TD Asset Management Inc. (1.03%). Company insiders that own BioAmber stock include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Mario Settino and Michael A Hartmann. View Institutional Ownership Trends for BioAmber.

Who sold BioAmber stock? Who is selling BioAmber stock?

BioAmber's stock was sold by a variety of institutional investors in the last quarter, including Robecosam AG. View Insider Buying and Selling for BioAmber.

Who bought BioAmber stock? Who is buying BioAmber stock?

BioAmber's stock was bought by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., TD Asset Management Inc., Bank of New York Mellon Corp, Vanguard Group Inc. and FMR LLC. Company insiders that have bought BioAmber stock in the last two years include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Mario Settino and Michael A Hartmann. View Insider Buying and Selling for BioAmber.

How do I buy BioAmber stock?

Shares of BioAmber can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioAmber's stock price today?

One share of BioAmber stock can currently be purchased for approximately $0.52.

MarketBeat Community Rating for BioAmber (NYSE BIOA)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about BioAmber and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioAmber (NYSE:BIOA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.00 (477.48% upside)

Analysts' Ratings History for BioAmber (NYSE:BIOA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Cowen and CompanySet Price TargetHold$3.00HighView Rating Details
3/13/2017AltaCorp CapitalDowngradeOutperform -> SpeculativeMediumView Rating Details
8/7/2016Canaccord GenuityReiterated RatingBuy$5.50N/AView Rating Details
3/28/2016Credit Suisse GroupBoost Price TargetOutperform$15.00 -> $17.00N/AView Rating Details
1/5/2016HC WainwrightReiterated RatingBuy$18.00N/AView Rating Details
1/5/2016Rodman & RenshawInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for BioAmber (NYSE:BIOA)
Earnings by Quarter for BioAmber (NYSE:BIOA)
Earnings History by Quarter for BioAmber (NYSE BIOA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.16)N/AView Earnings Details
8/3/20176/30/2017($0.17)($0.20)$4.09 million$4.12 millionViewListenView Earnings Details
5/9/20173/31/2017($0.13)($0.31)$3.65 million$2.12 millionViewListenView Earnings Details
3/16/201712/31/2016($0.19)($0.31)$3.77 million$0.63 millionViewN/AView Earnings Details
11/3/2016Q216($0.22)($0.26)$3.75 million$3.66 millionViewN/AView Earnings Details
8/9/2016Q116($0.27)($0.25)$2.37 million$2.50 millionViewN/AView Earnings Details
3/14/2016Q415($0.35)($0.40)$0.98 million$1.11 millionViewN/AView Earnings Details
11/4/2015Q315($0.41)($0.27)$2.30 million$0.35 millionViewN/AView Earnings Details
3/12/2015Q414($0.39)($0.48)($0.31) millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.40)($0.41)$0.47 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.40)$0.40$0.45 million$0.42 millionViewN/AView Earnings Details
3/13/2014($0.36)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioAmber (NYSE:BIOA)

No earnings estimates for this company have been tracked by


Dividend History for BioAmber (NYSE:BIOA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioAmber (NYSE:BIOA)
Insider Ownership Percentage: 8.33%
Institutional Ownership Percentage: 37.40%
Insider Trades by Quarter for BioAmber (NYSE:BIOA)
Institutional Ownership by Quarter for BioAmber (NYSE:BIOA)
Insider Trades by Quarter for BioAmber (NYSE:BIOA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/18/2017Michael A HartmannInsiderBuy10,000$0.48$4,800.00View SEC Filing  
8/9/2017Mario SettinoCFOBuy15,000$0.53$7,950.00View SEC Filing  
11/9/2016George Frederick John GosbeeDirectorBuy25,000$3.87$96,750.00View SEC Filing  
11/8/2016Kurt W BrinerDirectorBuy10,000$3.84$38,400.00View SEC Filing  
5/24/2016Kurt W BrinerDirectorBuy1,000$3.69$3,690.00View SEC Filing  
5/23/2016Kurt W BrinerDirectorBuy21,015$3.61$75,864.15View SEC Filing  
5/11/2016Jean-Francois HucCEOBuy10,000$3.22$32,200.00View SEC Filing  
5/9/2016Kenneth W WallDirectorBuy13,227$3.11$41,135.97View SEC Filing  
5/6/2016Michael A HartmannEVPBuy3,000$3.44$10,320.00View SEC Filing  
12/3/2015Jean-Francois HucCEOSell27,278$8.11$221,224.58View SEC Filing  
12/3/2015Michael A. HartmannEVPSell21,477$8.11$174,178.47View SEC Filing  
8/14/2015Michael A HartmannEVPBuy1,500$6.75$10,125.00View SEC Filing  
8/11/2015Jean-Francois HucCEOBuy4,000$6.18$24,720.00View SEC Filing  
8/10/2015Raymond J LandDirectorBuy1,500$6.71$10,065.00View SEC Filing  
5/6/2015Jean-Francois HucCEOBuy8,800$9.00$79,200.00View SEC Filing  
5/6/2015Kurt W BrinerDirectorBuy10,000$9.00$90,000.00View SEC Filing  
5/6/2015Michael A HartmannEVPBuy1,100$9.00$9,900.00View SEC Filing  
12/11/2014Kenneth W WallDirectorBuy3,000$9.20$27,600.00View SEC Filing  
12/10/2014Kenneth W WallDirectorBuy5,000$9.30$46,500.00View SEC Filing  
11/10/2014Kurt W BrinerDirectorBuy15,000$9.35$140,250.00View SEC Filing  
9/9/2014Kurt W BrinerDirectorBuy5,000$12.00$60,000.00View SEC Filing  
8/25/2014Kurt W BrinerDirectorBuy14,250$11.50$163,875.00View SEC Filing  
8/11/2014Kurt W BrinerDirectorBuy2,980$11.45$34,121.00View SEC Filing  
7/16/2014Jean-Francois HucCEOBuy4,000$12.00$48,000.00View SEC Filing  
7/16/2014Michael A HartmannEVPBuy3,000$12.00$36,000.00View SEC Filing  
5/12/2014Andrew P AshworthCFOBuy3,000$10.00$30,000.00View SEC Filing  
5/12/2014Michael A HartmannEVPBuy2,500$10.05$25,125.00View SEC Filing  
11/14/2013Kurt W BrinerDirectorBuy7,200$6.95$50,040.00View SEC Filing  
9/3/2013Michael A HartmannEVPBuy2,000$4.63$9,260.00View SEC Filing  
8/29/2013Jean-Francois HucCEOBuy5,000$4.25$21,250.00View SEC Filing  
8/15/2013Kurt W BrinerDirectorBuy13,000$5.49$71,370.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioAmber (NYSE:BIOA)
Latest Headlines for BioAmber (NYSE:BIOA)
DateHeadline logoReviewing Innospec (IOSP) & BioAmber (BIOA) - September 19 at 12:48 AM logoForm 8-K BioAmber Inc. For: Sep 11 - - September 16 at 4:15 PM logoBioAmber Announces New Chief Executive Officer - September 14 at 5:14 PM logoAnalyzing BioAmber (BIOA) and Its Rivals - September 13 at 6:22 PM logoBioAmber Inc. Receives Notice of Non-Compliance from the NYSE - September 13 at 5:42 PM logoBRIEF-Sabby Management LLC reports 6.15 pct passive stake in BioAmber inc - SEC filing‍ - September 13 at 3:07 AM logoForm SC 13G BioAmber Inc. Filed by: SABBY MANAGEMENT, LLC - - September 12 at 4:50 PM logoBRIEF-NN Group N.V. reports 15.91 pct passive stake in Bioamber - September 8 at 10:00 PM logoKronos Worldwide (KRO) versus BioAmber (BIOA) Head-To-Head Review - September 2 at 2:26 AM logoBioAmber, Inc. :BIOA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 - August 25 at 6:18 PM logoHead to Head Review: Ferro Corporation (FOE) versus BioAmber (BIOA) - August 14 at 12:52 PM logoBioAmber Inc. (BIOA) Stock Rating Lowered by ValuEngine - August 8 at 11:28 PM logoBioAmber (BIOA) Prices $11M Offering of Common Stock, Warrants - August 8 at 9:23 PM logoBRIEF-Bioamber prices public offering of 14.7 mln shares at $0.75/shr - August 8 at 9:23 PM logoMid-Afternoon Market Update: Michael Kors Gains On Earnings Beat; Commercial Vehicle Shares Slide - Nasdaq - August 8 at 4:20 PM logoMid-Day Market Update: Stocks Turn Higher; Depomed Shares Plummet - Nasdaq - August 8 at 4:20 PM logoBioAmber Inc. Announces US$11 Million Underwritten Offering of Common Stock and Warrants - MarketWatch - August 8 at 4:20 PM logoBioAmber Inc. Announces US$11 Million Underwritten Offering of Common Stock and Warrants - August 8 at 4:20 PM logoBioAmber Inc. Announces Underwritten Offering of Common Stock and Warrants - MarketWatch - August 8 at 3:05 AM logoBioAmber (BIOA) Announces Underwritten Common Offering - August 7 at 10:05 PM logoBRIEF-BioAmber announces underwritten offering of common stock and warrants - August 7 at 5:04 PM logoBioAmber Inc. Announces Underwritten Offering of Common Stock and Warrants - August 7 at 5:04 PM logoBioAmber's (BIOA) Management on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 6 at 4:02 PM logoBioAmber announces record revenues for the second quarter 2017 and purchase of Mitsui equity stake in Sarnia Joint ... - PR Newswire (press release) - August 4 at 9:50 PM logoBioAmber Inc. (BIOA) Issues Earnings Results - August 4 at 8:58 PM logoEdited Transcript of BIOA earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 3 at 11:02 PM logoInvestor Network: BioAmber, Inc. to Host Earnings Call - August 3 at 6:01 PM logoBioAmber announces record revenues for the second quarter 2017 and purchase of Mitsui equity stake in Sarnia Joint Venture - August 3 at 6:01 PM logoBioAmber reports 2Q loss - August 3 at 6:01 PM logoBioAmber Announces Webcast of Fiscal Second Quarter 2017 Financial Results - August 1 at 5:25 PM logoBioAmber Inc. (BIOA) Set to Announce Earnings on Monday - July 31 at 8:11 AM logoGlobal Organic Acid Market By Type (Acetic Acid, Citric Acid, Formic Acid and Lactic Acid), By End Uses (Industrial ... - PR Newswire (press release) - July 27 at 10:03 PM logoBioAmber Inc. (NYSE:BIOA) Upgraded to Hold by Zacks Investment Research - July 26 at 5:02 PM logoGlobal Bio-Based Chemicals Market Forecast 2017-2025 - PR Newswire (press release) - July 20 at 11:11 PM logoSuccinic Acid - Global Strategic Business Report 2017 - Rising Demand for Bio-Plastics: Opportunity for Bio-Succinic Acid Market - July 16 at 9:11 PM logoBioAmber Inc. (BIOA) Rating Lowered to Sell at Zacks Investment Research - July 11 at 7:14 PM logoComparing BioAmber (NYSE:BIOA) and Kraton Corporation (KRA) - July 9 at 8:22 AM logoBioAmber (NYSE:BIOA) & Rayonier Advanced Materials (RYAM) Head-To-Head Comparison - July 7 at 8:06 AM logoBioAmber Inc. (BIOA) Lifted to Sell at ValuEngine - June 24 at 12:38 AM logoBioAmber (BIOA) Announces Launch of BIO-SA Pharmaceutical Grade - - June 16 at 4:39 PM logoBioAmber (BIOA) Announces Launch of BIO-SA Pharmaceutical Grade - June 15 at 5:43 PM logoBioAmber Launches a Pharmaceutical Grade for its Bio-succinic Acid - June 15 at 5:43 PM logoBioAmber Inc. (BIOA) Lowered to "Strong Sell" at ValuEngine - June 12 at 12:40 AM logoTMX Group Equity Financing Statistics - May 2017 - June 7 at 4:12 PM logoGlobal Organic Acid Market, Competition Forecast and Opportunities, 2026 - Research and Markets - May 29 at 9:13 AM logoBioAmber Announces Changes to its Board of Directors, the Appointment of a Chief Financial Officer and the Results ... - PR Newswire (press release) - May 17 at 8:59 PM logoLaw Offices of Howard G. Smith Reminds BioAmber Inc. Investors of Pending Lawsuit and Upcoming Lead Plaintiff ... - Business Wire (press release) - May 17 at 8:59 PM logoLaw Offices of Howard G. Smith Reminds BioAmber Inc. Investors of Pending Lawsuit and Upcoming Lead Plaintiff Deadline - May 16 at 4:00 PM logoBIOA DEADLINE ALERT: The Law Offices of Vincent Wong Notifies Investors of BioAmber Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2017 - BIOA - May 16 at 4:00 PM logoBIOA ALERT: Rosen Law Firm Reminds BioAmber Inc. Investors of Important May 17 Deadline in First Filed Class Action - BIOA - May 16 at 12:37 PM



BioAmber (BIOA) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff